Actelion to Announce FY 2006 Results and R&D Update on 22 February 2007
February 19, 2007 11:30 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Feb. 19, 2007 (PRIME NEWSWIRE) -- Actelion Ltd. will announce the financial full-year 2006 results on Thursday, 22 February 2007 at 07.00 CET / 06.00 GMT / 01.00 a.m....
Successful Proof-of-Concept With Actelion's Orexin Receptor Antagonist in Patients Suffering From Primary Insomnia -- First Demonstration of Key Role of Orexin System in Humans Suffering From Sleep Disorders
February 05, 2007 01:00 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Feb. 5, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that the proof-of-concept study in patients with primary insomnia receiving Actelion's Orexin-OX1/OX2...
Publication in Nature Medicine Highlights Potential of Actelion's Orexin Receptor Antagonist as a Novel Mechanism to Treat Sleep Disorders
January 29, 2007 01:24 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Jan. 29, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today the publication of both pre-clinical and placebo-controlled clinical data in the February edition of...
Actelion Ltd. Announces Successful Completion of Its Cash Tender Offer for Shares of CoTherix, Inc.
January 09, 2007 01:00 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Jan. 9, 2007 (PRIME NEWSWIRE) -- Actelion Ltd. (SWX:ATLN) announced today that an indirect wholly-owned subsidiary, Curl Acquisition Subsidiary, Inc., has acquired a majority...
Actelion Announces Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
December 18, 2006 02:04 ET
|
Actelion Ltd.
-- Significant reduction in pulmonary vascular resistance
-- Strong trend towards improvement in exercise capacity
-- Significant delay in time to clinical worsening
-- Full data analysis...
Actelion-1 -- First Tissue-Targeting Endothelin Receptor Antagonist -- in Phase III for Pulmonary Hypertension
December 11, 2006 01:01 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Dec. 11, 2006 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that it has initiated a comprehensive Phase III program for Actelion-1, the first tissue targeting...
Actelion Ltd. Announces Commencement of Cash Tender Offer for CoTherix, Inc. and HSR Clearance to Acquire CoTherix, Inc.
December 08, 2006 01:10 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Dec. 8, 2006 (PRIME NEWSWIRE) -- Actelion Ltd. (SWX:ATLN) announced today that its indirect wholly owned subsidiary, Curl Acquisition Subsidiary, Inc., is commencing a cash...
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
November 20, 2006 02:04 ET
|
Actelion Ltd.
-- Strengthening Actelion's strong role in advancing PAH therapy
-- Strengthening the reach of Ventavis(r) in the United States
-- Immediate positive effect expected on 2007 cash earnings
--...
Actelion Announces 9-Month Results for 2006
October 19, 2006 01:57 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Oct. 19, 2006 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced its financial results for the first nine months of 2006. With total net revenues for the first nine months...
Actelion Ltd: Detailed Analysis of CONSCIOUS-1 Presented at CNS
October 09, 2006 12:13 ET
|
Actelion Ltd.
CHICAGO and ALLSCHWIL, Switzerland, Oct. 9, 2006 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today that the detailed analysis of the dose-finding study CONSCIOUS-1 (Clazosentan...